Latest Regulatory Approvals News

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Rapid Critical Metals has launched a comprehensive scoping study for its NSW silver projects, backed by promising drilling results and advanced ore-sorting technology.

29Metals Limited has initiated a fully underwritten $150 million entitlement offer at $0.40 per share, aiming to bolster its growth projects and operational recovery following seismic disruptions. The retail offer opens on 28 January and closes on 11 February 2026.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

Aurora Energy Metals has taken significant strides in its uranium exploration strategy, progressing Eagle Energy Metals’ planned Nasdaq listing and securing new Western Australian exploration assets. These developments position the company for growth amid evolving market dynamics.

Sprintex Limited has secured its largest-ever €15.6 million purchase order with Mest Water, marking a pivotal shift from technology validation to commercial deployment. Supported by favourable European regulations and expanding markets in India, the company is poised for sustained revenue growth.

Key Petroleum Limited progresses its Potential Commercial Area applications in Queensland’s Cooper-Eromanga Basin, anticipating government approval by year-end, while planning a capital raise to bolster its limited cash reserves.